Corporate News
Page 2
Feb 06, 2025
Gameto Announces FDA IND Clearance for Fertilo utilizing REPROCELL’s StemRNA™ Clinical Seed iPSCs
Gameto's FDA IND clearance for Fertilo marks a milestone as the first iPSC-based therapy enters U.S. Phase 3 trials, leveraging REPROCELL’s StemRNA™ Clinical Seed iPSCs.
Jan 14, 2025
World’s First Live Birth Using REPROCELL’s StemRNA Clinical Seed iPSCs for Oocyte Maturation Outside of the Body
REPROCELL is thrilled to celebrate a groundbreaking milestone by our partner Gameto, who recently announced the birth of the first baby born using Fertilo, a proprietary in vitro oocyte maturation technology.
Jan 10, 2025
PRESS RELEASE: Qkine announces partnership with REPROCELL: Global distributorship for high quality bioactive proteins for stem cell culture
Qkine Ltd., and REPROCELL Inc., have partnered to globally distribute high-quality proteins such as growth factors and cytokines manufactured by Qkine.
Nov 13, 2024
PRESS RELEASE: New Study Highlights Role of Stromal Support in Bioengineered Human Intestinal Models
New study by Prof Stefan Przyborski at Durham University enhances drug testing models with stromal support in bioengineered human intestinal tissue.
Jul 22, 2024
PRESS RELEASE: Bioserve India Launches Advanced Stem Cell Products
Discover Bioserve India's advanced stem cell products, supporting innovation in research and drug development.
May 30, 2024
REPROCELL USA Inaugurates GMP Manufacturing Facility for Stem Cells
REPROCELL USA unveils GMP manufacturing facility for hiPSC and hMSC, revolutionizing stem cell therapy with closed-system technology.
May 17, 2024
PRESS RELEASE: Bioserve Biotechnologies and RISVI Trading Announce New Distributorship Agreement in Qatar
A new distributorship agreement between Bioserve Biotechnologies and RISVI Trading in Qatar, expanding access to molecular biology products and services.
May 16, 2024
PRESS RELEASE: Our StemRNA Clinical Seed iPSCs Power Breakthrough in Women's Health!
An exciting breakthrough in women's health with our StemRNA Clinical Seed iPSCs powering innovative fertility treatment by Gameto.
May 14, 2024
PRESS RELEASE: REPROCELL Announces Partnership with Nova Natura UAB, Expanding Distribution Reach in Baltic Region
REPROCELL and UAB Nova natura enter a new distributor agreement to serve the Baltic region.
Apr 18, 2024
New from REPROCELL: GMP Grade Stem Cell Master Cell Bank Service Expansion
REPROCELL announces the acquisition of a self-contained GMP system to expand our GMP capabilities.
Feb 08, 2024
PRESS RELEASE: REPROCELL’s New Clinical Pipeline: Tumor Infiltrating Lymphocyte Infusion Therapy (TIL Therapy)
REPROCELL will soon add a third clinical pipeline, TIL therapy for cervical cancer, in addition to Stemchymal for spinocerebellar ataxia, and iPSC-derived neuroglial cells for ALS.
Jan 31, 2024
Histocell obtains AEMPS authorisation and GMP certification for its new manufacturing plant for cell therapy and associated biological medicinal products in Larrabetzu
REPROCELL's clinical stem cells manufacturing partner Histocell has obtained AEMPS authorisation and GMP certification for its new manufacturing plant.
Jan 15, 2024
Cellcolabs announces partnership with REPROCELL: Global distributorship for research- and GMP-grade MSC and MSC derivatives
SOLNA, Sweden and YOKOHAMA, Japan – Cellcolabs AB, a spin-out of the Karolinska Institute specialized in manufacturing both research- and GMP-grade mesenchymal stem cells (MSC), and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, have partnered to globally distribute the high-quality MSCs and MSC derivatives manufactured by Cellcolabs for research and clinical applications. This agreement also includes exclusive distribution in Japan.
Dec 15, 2023
End of 2023 Newsletter
Discover the latest advancements in stem cell and drug discovery research at REPROCELL. From GMP MSC production to Pharmacology-AI services, explore how REPROCELL is revolutionizing the field. Stay updated with their collaborations and partnerships for precision medicine and clinical capabilities.
Oct 24, 2023
REPROCELL supports Silo Pharma with successful human tissue testing in Rheumatoid Arthritis study
REPROCELL supports Silo Pharma research success, investigating the effects of SPU-21 Peptide on rheumatoid arthritis in a human synovial tissue study
Oct 04, 2023
REPROCELL Announces License Agreement with Gameto for the Advancement of its Program to Improve Assisted Fertility using iPSCs
Gameto plans to use the iPSC line to advance its program, Fertilo, designed to improve IVF and egg freezing.
Sep 27, 2023
Bioserve Biotechnologies Partners with BioMavericks Ltd. to Expand Presence in the UK market
[Hyderabad, India, 27 September 2023] – Bioserve Biotechnologies (India) Pvt Limited, is teaming up with BioMavericks Ltd., a UK-based company.
Jul 13, 2023
Innovation Unleashed: REPROCELL's Q1 Recap and Insights
REPROCELL had a productive first quarter of 2023-24, launching new services, winning grants, and publishing research. Find out more in our news release.
Jul 11, 2023
Vernal Biosciences Announces Partnership With REPROCELL: Exclusive Distributorship in Japan for mRNA and LNP Formulation Services
Vernal Biosciences, a leader in mRNA and LNP manufacturing, and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, have partnered to provide mRNA services in Japan at scale for research and clinical applications
Jun 28, 2023
Joint Research Agreement with Keio University on Tumor-Infiltrating Lymphocyte Therapy for Cervical Cancer
REPROCELL has entered into a joint research agreement with Keio University regarding the transfer of technology to produce Tumor Infiltrating Lymphocytes (TIL).